PerspectivesThere is an interesting perspective presented by F6 on Investor Village regarding valuation of the share price. From my perspective I believe we are currently undervalued based on the fact that apabetalone is in the phase lll BETonMACE trial and is the
only BET inhibitor in trial for cardiac health issues (it's unique and has an 8 year lead according to Don) and new trials already started in CKD. They also have 2 DSMB (data safety monitoring board) reports and the trial is moving ahead well. Add to this the diabetes mellitus positive impacts.
If BETonMACE succeeds I'm more in agreement with the type of valuation numbers provided by F6.
Short term we seem to have some drags on the value;
- The line of credit uncertainty (not an issue for me...but some investors seem concerned).
- The psychlogical baggage hangover from the ASSURE trial.
- Lack of a NASDAQ listing.
- Low profile (which for current investors is a great advantage).
- Lack of independent analyst coverage. (see tundups post on Agora re the Cowen conference - should be positive for RVX and that seemed to be evident in the price and volume post Cowen).
On the other side of the equation from my perspective we are seeing new and unexpected drivers;
- I'm referring specifically to the 2 independent research papers on apabetalone regarding retinitus pigmentosis and (FSHD) muscular dystrophy. (as Don pointed out these types of deals could lead to licensing agreements. If money finally started to flow into RVX with these types of deals I believe it could have a huge impact).
- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced preliminary results from the New Zealand based Phase 1 trial with severe kidney (renal) impaired patients. The data showed remarkable results in reducing inflamed protein biomarkers in patients with severe kidney impairment versus healthy control patients. It is believed that this is the first time in medical history that a direct connection of this type can be made between epigenetic regulation and its potential for positive disease impact.
- Positive type B FDA meeting related to phase 2a kidney dialysis trial.
- The dramatic increase in scientific papers related to epigenetics and BET inhibition.
- And there are other developments like in the area of orphan trials which if successful could move apabetalone to market quickly.
We should hear about, at some point, the next licensing agreement. This will be very telling in terms of the future direction of this company...Hepalink USA, Boehringer-Ingelheim in Europe, AZ, etc.
One of the things that puzzles me is that I have heard very little perspective about the patent(value) that RVX holds on the combination of apabetalone and rosuvastatin (Crestor) which was a combination in the post hoc findings accociated with the 55% RRR of 5 pt MACE and the 77% RRR of MACE in patients with diabetes mellitus. From what I recall this patent goes through 2029 but recently Don mentioned something about 2034.
I am rambling again and doing too much from recall so DYODD and GLTA.
Toinv